Global  

Bharat Biotech's indigenous COVID-19 vaccine 'COVAXIN' gets approval for phase I & II human clinical trials

DNA Tuesday, 30 June 2020 ()
The SARS-CoV-2 strain was isolated in NIV, Pune and transferred to Bharat Biotech. The indigenous inactivated vaccine was developed and manufactured in Bharat Biotech's BSL-3 (Bio-Safety Level 3) High Containment facility located in Genome Valley, Hyderabad.
0
shares
ShareTweetSavePostSend
 
Video credit: KTNV Channel 13 Las Vegas - Published
News video: Race to create a vaccine

Race to create a vaccine 02:29

The race to create a coronavirus vaccine is picking up. 17 possible vaccines are in clinical evaluation, with one already in wide-scale human trials.

Related videos from verified sources

China Approves COVID-19 Vaccine For Human Trials In Military Personnel [Video]

China Approves COVID-19 Vaccine For Human Trials In Military Personnel

Chinese officials have announced the approval of a COVID-19 vaccine for immediate use by military personnel. According to UPI. the vaccine, Ad5-nCoV is currently being studied in clinical..

Credit: Wochit     Duration: 00:30Published
Covid-19 vaccine: India ready for human trials of indigenously developed Covaxin | Oneindia News [Video]

Covid-19 vaccine: India ready for human trials of indigenously developed Covaxin | Oneindia News

India is now ready for clinical trials of a potential covid 19 vaccine approved by the Drug controller general of India. Covaxin will enter Phase I and II human trilas from July across the..

Credit: Oneindia     Duration: 01:17Published
Wisconsin researchers in race for coronavirus vaccine [Video]

Wisconsin researchers in race for coronavirus vaccine

There is a race for a coronavirus vaccine in research labs across the globe, and that include inside FluGen, a small lab in Madison partnering with the University of Wisconsin and Bharat Biotech, a..

Credit: WISN     Duration: 01:23Published

Related news from verified sources

DCGI gives nod to Bharat Biotech to conduct phase I and II Human clinical trials to develop vaccine

New Delhi: The Drug Controller General of India (DCGI) has granted permission to Bharat Biotech International Limited (BBIL) to conduct Phase I and II Human...
Mid-Day


Tweets about this